Evidence map›Paper›PMID 28031872›Full record

ReviewFuture science OA2015

Possible roles of amyloids in malaria pathophysiology.

Ernest Moles, Juan José Valle-Delgado, Patricia Urbán, Isabel G Azcárate, José M Bautista, Javier Selva, Gustavo Egea, Salvador Ventura, Xavier Fernàndez-Busquets

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future science OA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Protein misfolding diseases.Future science OA · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Ernest MolesNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain; Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
Juan José Valle-DelgadoNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain; Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
Patricia UrbánNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain; Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
Isabel G AzcárateDepartment of Biochemistry & Molecular Biology IV, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Research Institute Hospital 12 de Octubre, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Department of Biochemistry & Molecular Biology IV, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Research Institute Hospital 12 de Octubre, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain.
José M BautistaDepartment of Biochemistry & Molecular Biology IV, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Research Institute Hospital 12 de Octubre, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Department of Biochemistry & Molecular Biology IV, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain; Research Institute Hospital 12 de Octubre, Universidad Complutense de Madrid, Ciudad Universitaria, ES-28040 Madrid, Spain.
Javier SelvaDepartment of Cell Biology, Immunology & Neurosciences, University of Barcelona School of Medicine & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES-08036 Barcelona, Spain; Department of Cell Biology, Immunology & Neurosciences, University of Barcelona School of Medicine & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES-08036 Barcelona, Spain.
Gustavo EgeaDepartment of Cell Biology, Immunology & Neurosciences, University of Barcelona School of Medicine & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES-08036 Barcelona, Spain; Department of Cell Biology, Immunology & Neurosciences, University of Barcelona School of Medicine & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), ES-08036 Barcelona, Spain.
Salvador VenturaInstitut de Biotecnologia i Biomedicina & Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, ES-08193 Bellaterra, Spain; Institut de Biotecnologia i Biomedicina & Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, ES-08193 Bellaterra, Spain.
Xavier Fernàndez-BusquetsNanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain; Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixac 10-12, ES-08028 Barcelona, Spain; Barcelona Institute for Global Health (ISGlobal, Hospital Clínic-Universitat de Barcelona), Rosselló 149-153, ES-08036 Barcelona, Spain.
Institute for Bioengineering of Catalonia · ESUniversitat de Barcelona · ESBarcelona Institute for Global Health · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESResearch Institute Hospital 12 de Octubre · ESUniversidad Complutense de Madrid · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main therapeutic and prophylactic tools against malaria have been locked for more than a century in the classical approaches of using drugs targeting metabolic processes of the causing agent, the protist

Indexed as

amyloidsintrinsically unstructured proteinsmalariaprions

Identifiers

PMID28031872
PMCPMC5137859
OpenAlexW1826669387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.